Surgical Salvage Improves Survival in Metastatic Oropharyngeal Cancer
the Cancer Therapy Advisor take:
Improved overall survival (OS) was found to be associated with surgical salvage in patients with recurrent locoregional and distant metastatic oropharyngeal squamous cell carcinoma (OPSCC), independent of human papillomavirus (HPV) tumor status, according to an article published online in the journal Cancer.
Participants in the study included patients with recurrent OPSCC from two institutions from 2000 to 2012. Immunohistochemistry and/or in situ hybridization were used to evaluate the status of each patient’s tumor. Kaplan-Meier and Cox proportional hazards methods were used to evaluate OS.
The majority of patients (80 out of 108) were HPV-positive, 65 of the patients had locoregional metastatic first recurrences and 43 had distant metastatic first recurrences. HPV-positive tumor status was found to be related to a longer time to disease recurrence (P<0.01). Several factors have an independent association with OS after disease recurrence: HPV-positive tumor status (aHR = 0.23; 95% CI: 0.09, 0.58;P=0.002), longer time to disease recurrence (≥1 year; aHR = 0.36; 95% CI: 0.18, 0.74; P=0.006), and surgical salvage (aHR = 0.26; 95% CI: 0.12, 0.61; P=0.002). Furthermore, researchers found an independent association between surgical salvage and improved OS compared with nonsurgical treatment among patients with both locoregional (aHR = 0.15; 95% CI: 0.04, 0.56; P=0.005) and distant (aHR = 0.19; 95% CI: 0.05, 0.75; P=0.018) metastatic disease recurrences.
The study suggests that further data be obtained to confirm the impact of surgical salvage on OS among patients with distant metastases.
Improved overall survival found to be associated with surgical salvage in metastatic oropharyngeal squamous cell carcinoma.
Surgical salvage was found to be associated with improved OS for patients with recurrent locoregional and distant metastatic OPSCC, independent of HPV tumor status.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma